1.Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer.
Kyeong Hyun KIM ; Seo Young SONG ; Kyu Hyoung LIM ; Seon Sook HAN ; Se Hyun KIM ; Jun Hwi CHO ; Chan Woo PARK ; Seoungkoo LEE ; Hui Young LEE
Cancer Research and Treatment 2013;45(1):74-77
Pemetrexed is approved as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. Pemetrexed has a modest toxicity profile and has not traditionally been regarded as a cause of interstitial pneumonitis. Here, we report on a rare case of pemetrexed-induced pneumonitis in a patient with NSCLC.
Adenocarcinoma
;
Carcinoma, Non-Small-Cell Lung
;
Cisplatin
;
Disease Progression
;
Glutamates
;
Guanine
;
Humans
;
Induction Chemotherapy
;
Lung Diseases, Interstitial
;
Pneumonia
;
Pemetrexed